“Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s604, https://doi.org/10.25251/2ddr5090.